Empagliflozin in Patients with Acute Heart Failure and Diuretic Resistance: Preliminary Data from the DRIP-AHF-1 Trial
Abstract
. Background: Dialysis patients are known to be at high cardiovascular risk, and the Agatston CAC score, a measure of coronary artery calcification, has been associated with cardiovascular events. Recently, calcimimetics such as etelcalcetide have been used to manage secondary hyperparathyroidism, but their effect on vascular calcification is unknown. Therefore, the present study investigated whether etelcalcetide use affects changes in Agatston CAC scores in maintenance hemodialysis patients. Methods: This historical cohort study included 192 patients undergoing maintenance hemodialysis who had Agatston CAC score of 100 or higher and were not using calcimimetics other than etelcalcetide. Propensity score matching was performed by age, gender, diabetes mellitus, Ca, iP, and intact PTH. In addition, we examined whether there was a difference in etelcalcetide use and the rate of change in Agatston CAC score after one year. Results: In the two groups of patients matched for background factors by propensity scores (18 patients each), the Agatston CAC score change was significantly lower in the etelcalcetide use group (p = 0.0284). Conclusions: Etelcalcetide use in maintenance dialysis patients may reduce coronary calcification.
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 192 participants or records.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.